Adding Imfinzi (durvalumab) to Bacillus Calmette-Guérin (BCG) therapy helped patients with high-risk, non-muscle invasive ...
Durvalumab addition to BCG therapy significantly improved DFS in BCG-naive, high-risk NMIBC patients, achieving a 32% reduction in DFS event risk. The combination therapy was well-tolerated, with ...
Discover a study exploring lower urinary tract injuries in pelvic fractures, highlighting diagnosis challenges, early CT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback